News

 

NEWS

Startup Miroculus Shares Vision for Rapid, Inexpensive miRNA Diagnostics at Tri-Con

Molecular diagnostics startup Miroculus is going all in on microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases and even tracking an individual’s general physiological well-being at the point of care and in resource-poor areas of the world, the company’s chief technology officer said this week. In a keynote presentation at Cambridge Healthtech Institute’s Molecular […]

Read more

IBM Watson adds Tiatros patient-centered social network to system

San Francisco start-up Tiatros, a doctor-driven, patient-centered social network, has joined the IBM Watson Ecosystem, the companies announced March 2 at HIMSS16. Tiatros was designed to allow physicians, with the consent of patients, to create a social network around the patient, including all doctors involved in their treatment and their family members. The first user of the platform was the […]

Read more

Immucor and Sirona Genomics receive the CE mark for Mia Fora NGS system for HLA typing

Immucor and Sirona Genomics announced this week that they have received the CE mark for their Mia Fora NGS system for HLA typing. The system is a high-resolution HLA typing solution for accurate coverage and analysis of 11 HLA genes. It is adapted for use on the Illumina MiSeq. The companies expect to launch a higher volume testing kit for […]

Read more

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth QB3@953, a biotech incubator, has been so successful that many of the startups housed there are searching for larger laboratories in Southside San Francisco. But their moves have been stymied by high rents and real estate prices, as well as a lack of space for midsize companies. The incubator, launched almost […]

Read more

Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors

Pfizer ($PFE) announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease […]

Read more

Amarantus Inks Deal to Merge Dx Unit with Avant Diagnostics

NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings announced today that it has signed a letter of intent to merge its Amarantus Diagnostics subsidiary with Avant Diagnostics. Upon the close of the merger, Avant will issue Amarantus Bio 80 million shares of its common stock, representing roughly 45 percent of the combined company’s outstanding shares. Avant will also issue Amarantus Bio […]

Read more

Dementia Discovery Fund Chooses Alector for First Investment

LONDON—A promising new avenue in Alzheimer’s research that focuses on the eradication of brain plaque by the immune system has become the first investment for a $100 million fund dedicated to delivering new dementia drugs within a decade. The Dementia Discovery Fund, set up last year with backing from the U.K. government and several of the world’s biggest pharmaceutical companies, […]

Read more

Alector Announces $29.5M Series D Financing

Alector Announces $29.5M Series D Financing Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, today announced that it has raised $29.5 million in a Series D financing. After having completed a Series C financing of $32 million earlier in the year, this financing brings the total amount […]

Read more

4D Molecular Therapeutics Announces Collaboration With Pfizer, Inc.

4D Molecular Therapeutics Announces Collaboration With Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and a collaboration and license agreement with Pfizer Inc. to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease […]

Read more

Fay Christodoulou, CSO, Miroculus

The notion of small molecules that detect dozens of cancers may sound like something out of a science-fiction novel. But for Christodoulou and her peers at Miroculus, it’s more akin to a modern-day reality. The company has trained its sights on microRNA, which Christodoulou describes as small molecules that reflect a person’s health state and which might be used as […]

Read more
Page 4 of 8« First...23456...Last »

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter